» Articles » PMID: 36973407

Nucleotide Metabolism: a Pan-cancer Metabolic Dependency

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2023 Mar 27
PMID 36973407
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic alterations are a key hallmark of cancer cells, and the augmented synthesis and use of nucleotide triphosphates is a critical and universal metabolic dependency of cancer cells across different cancer types and genetic backgrounds. Many of the aggressive behaviours of cancer cells, including uncontrolled proliferation, chemotherapy resistance, immune evasion and metastasis, rely heavily on augmented nucleotide metabolism. Furthermore, most of the known oncogenic drivers upregulate nucleotide biosynthetic capacity, suggesting that this phenotype is a prerequisite for cancer initiation and progression. Despite the wealth of data demonstrating the efficacy of nucleotide synthesis inhibitors in preclinical cancer models and the well-established clinical use of these drugs in certain cancer settings, the full potential of these agents remains unrealized. In this Review, we discuss recent studies that have generated mechanistic insights into the diverse biological roles of hyperactive cancer cell nucleotide metabolism. We explore opportunities for combination therapies that are highlighted by these recent advances and detail key questions that remain to be answered, with the goal of informing urgently warranted future studies.

Citing Articles

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.

PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.


Cultivation methods and biology of Lentinula edodes.

Song X, Shang X, Zhang M, Yu H, Zhang D, Tan Q Appl Microbiol Biotechnol. 2025; 109(1):63.

PMID: 40067479 PMC: 11897120. DOI: 10.1007/s00253-024-13387-w.


Combined Analysis of Transcriptomes and Metabolomes Reveals Key Genes and Substances That Affect the Formation of a Multi-Species Biofilm by Nine Gut Bacteria.

Zhang T, Pei Z, Wang H, Zhao J, Chen W, Lu W Microorganisms. 2025; 13(2).

PMID: 40005603 PMC: 11857192. DOI: 10.3390/microorganisms13020234.


Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism.

Yan L, Liu Y, Huang Y, Sun X, Jiang H, Gu J Cancer Biol Med. 2025; 22(2).

PMID: 39995202 PMC: 11899589. DOI: 10.20892/j.issn.2095-3941.2024.0385.


KAT7-acetylated YBX1 promotes hepatocellular carcinoma proliferation by reprogramming nucleotide metabolism.

Huang H, Ren L, Zhou Y, Chen P, Zhao H, Li S BMC Cancer. 2025; 25(1):311.

PMID: 39984921 PMC: 11844059. DOI: 10.1186/s12885-025-13708-w.


References
1.
Tong X, Zhao F, Thompson C . The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev. 2009; 19(1):32-7. PMC: 2707261. DOI: 10.1016/j.gde.2009.01.002. View

2.
Olou A, King R, Yu F, Singh P . MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism. Oncogene. 2020; 39(16):3381-3395. PMC: 7165067. DOI: 10.1038/s41388-020-1225-4. View

3.
Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

4.
Natale R, Wheeler R, Moore M, Dallaire B, Lynch W, Carlson R . Multicenter phase II trial of brequinar sodium in patients with advanced melanoma. Ann Oncol. 1992; 3(8):659-60. DOI: 10.1093/oxfordjournals.annonc.a058298. View

5.
Waltham M, Holland J, Robinson S, Winzor D, NIXON P . Direct experimental evidence for competitive inhibition of dihydrofolate reductase by methotrexate. Biochem Pharmacol. 1988; 37(3):535-9. DOI: 10.1016/0006-2952(88)90225-0. View